Close Menu

NEW YORK (GenomeWeb) – Agilent Technologies announced that the US Food and Drug Administration has granted expanded approval to the firm's companion diagnostic for the Merck PD-L1 inhibitor Keytruda (pembrolizumab). The Dako PD-L1 IHC 22C3 pharmDx test can now be used to determine expression status and inform treatment in a broader range of metastatic non-small cell lung cancer (NSCLC) patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
17

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.